iBio stock soars after amylin receptor antibody shows promising results

Published 24/06/2025, 13:58
© Reuters.

Investing.com -- iBio Inc (NASDAQ:IBIO) stock surged 50% after the company announced preclinical data showing its engineered amylin receptor agonist antibody reduced acute food intake by 60% in a mouse model of obesity.

The AI-driven biotech firm reported that its collaboration with AstralBio has yielded multiple novel engineered antibody agonists targeting the amylin receptor, a heterodimeric G protein-coupled receptor. The company’s approach focuses on selective activation of the amylin receptor rather than dual agonism of amylin and calcitonin receptors, which they believe could match or exceed DACRA efficacy with improved tolerability.

iBio’s technology allows precise targeting of the amylin receptor and its subtypes, positioning the company to potentially compete in the rapidly growing obesity treatment market. The amylin hormone naturally regulates satiety and delays gastric emptying, making its receptor a promising therapeutic target for obesity and cardiometabolic diseases.

The company noted that other amylin analogs in clinical development have achieved body weight reductions of up to 22.7% when used with semaglutide and 11.8% as monotherapy. iBio’s approach targets different signaling pathways, potentially enhancing weight-loss efficacy when combined with GLP-1 receptor agonists or serving as an alternative for patients who don’t respond well to GLP-1-based treatments.

iBio leverages its proprietary Drug Discovery (NASDAQ:WBD) Platform and advanced AI to develop antibodies with high selectivity and potency, aiming to discover molecules that could become best-in-class therapeutics for weight management with optimal tolerability and lean mass preservation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.